Table I.
Association between MAPK10 expression and the characteristics of patients with NSCLC (n=31).
| MAPK10 expression | |||
|---|---|---|---|
| Characteristics | High | Low | P-value |
| Sex | 0.724 | ||
| Male | 9 | 7 | |
| Female | 7 | 8 | |
| Age, years | 0.999 | ||
| >55 | 10 | 9 | |
| ≤55 | 6 | 6 | |
| Histological type | 0.285 | ||
| Squamous cell carcinoma | 9 | 5 | |
| Adenocarcinoma | 7 | 10 | |
| Lymph node metastasis | 0.012 | ||
| Yes | 12 | 4 | |
| No | 4 | 11 | |
| TNM stage | 0.029 | ||
| I–II | 3 | 9 | |
| III–IV | 13 | 6 | |
| EGFR mutation | 0.722 | ||
| Yes | 8 | 6 | |
| No | 8 | 9 | |
| KRAS mutation | 0.458 | ||
| Yes | 4 | 6 | |
| No | 12 | 9 | |
MAPK10, mitogen-activated protein kinase 10; TNM, tumor-node- metastasis; EGFR, epidermal growth factor receptor.